Recognizing the interplay between sCD163, which acts as a surrogate of CD-163 positive TAMs burden, with CCL2 and CCL4 that enforce TAMs’ tumor infiltration, could reveal new biomarkers. The gene discussed is CCL2; the disease is neoplasm.